Targeting prandial hyperglycemia: How important is it and how best to do this?

Current Diabetes Reports

Volumn 8, Issue 5, 2008, Pages 368-374

  Monnier, Louis ^a   Colette, Claude ^b  

^a UNIV MONTPELLIER   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; UNCLASSIFIED DRUG;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC INDEX; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW; ARTICLE; BLOOD; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD;

EID: 58149401183     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0064-4     Document Type: Review

References (51)

1. Laakso M, Lehto S: Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997, 5:294-315.
2. Stratton IM, Adler AI, Neil HAW, et al.: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000, 321:405-412.
3. Sacks DB, Bruns DE, Goldstein DE, et al.: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2002, 25:750-786.
4. Monnier L, Colette C, Boniface H: Contribution of postprandial glucose to chronic hyperglycaemia: From the "glucose triad" to the trilogy of "sevens." Diabetes Metab 2006, 32:2S11-2S16.
5. Monnier L, ColetSe C: Glycemic variability: should we and can we prevent it? Diabetes Care 2008, 31(Suppl 2):S150-S154.
6. Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c. Diabetes Care 2003, 26:881-885.
7. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
8. Ceriello A: Postprandial hyperglycemia and diabetes complications. Is it time to treat? Diabetes 2005, 54:1-7.
9. Colette C, Monnier L: Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res 2007, 39:683-686.
10. International Diabetes Federation: Guideline for management of postmeal glucose. Presented at the 43rd European Association for the Study of Diabetes Annual Meeting. Amsterdam, The Netherlands. September 17-21, 2007:1-27. Available at http://www.idf.org/home/index.cfm?unode= 185108C7-1E27-4A03-9B73-01D54087E32E. Accessed June 16, 2008.
11. Dinneen S, Gerich JE, Rizza R: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992, 327:707-713.
12. Monnier L: Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest 2000, 30(Suppl 2):3-11.
13. Polonsky KS, Given BD, Hirsch L, et al.: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988, 318:1231-1239.
14. Monnier L, Colette C, Dunseath GJ, Owens DR: The loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. Diabetes Care 2007, 30:263-269.
15. DeFronzo RA: Lilly lecture 1987B The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667-687.
16. DeFronzo RA: Pathogenesis oM type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997, 5:177-269.
17. UK Prospective Diabetes Study Group 16: Overview of 6 year's therapy for type 2 diabetes: A progressive disease [no authors listed]. 1995, 44:1249-1258.
18. Levy J, Atkinson AB, Bell PM, et al.: Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast diet study. Diabet Med 1998, 15:290-296.
19. Monnier L, Colette C, Thuan J-F, Lapinski H: Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. Eur J Clin Invest 2006, 36:231-235.
20. Yki-Järvinen H: Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995, 38:1378-1388.
21. Boden G, Chen X, Urbain JL: Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM Caused by cyclic changes in hepatic glucose production. Diabetes 1996, 45:1044-1050.
22. Bolli GB, GericA JE: The dawn phenomenon: a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984, 310:746-750.
23. Bonora E, Corrao G, Bagnardi V, et al.: Prevalence and correlates of postprandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006, 49:846-854.
24. Rohlfing CL, Wiedmeyer HM, Little RR, et al.: Defining the relationship between plasma glucose and HbA1c: Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002, 25:275-278.
25. Avignon A, Radaceanu A, Monnier L: Non fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997, 20:1822-1826.
26. Bonora E, Calcaterra F, Lombardi S, et al.: Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001, 24:2023-2029.
27. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl 1):S5-S20.
28. Monnier L, Colette C, Rabasa-Lhoret R, et al.: Morning hyperglycemic excursions: A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002, 25:737-741.
29. Buckingham B, Block J, Wilson DM: Continuous glucose monitoring. Curr Opin Endocrinol Diabetes 2005, 12:273-279.
30. Lebovitz HE, Austin MM, Blonde L, et al.: ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006, 12(Suppl 1):6-12.
31. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
32. Ceriello A, Hanefeld M, Leiter L, et al.: Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004, 164:2090-2095.
33. Bonora E, Muggeo M: Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes, the epidemiologic evidence. Diabetologia 2001, 44:2107-2114.
34. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group [no authors listed]. Lancet 1999, 354:617-621.
35. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
36. Cavalot F, Petrelli A, Traversa M, et al.: Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: Lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006, 91:813-819.
37. Lachin JM, Genuth S, Nathan DM, et al.: Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008, 57:995-1001.
38. Hanefeld M, Fisher S, Schulze J, et al.: Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Interventional Study, 11-year follow-up. Diabetologia 1996, 39:1577-1583.
39. Esposito K, Giugliano D, Nappo F, Marfella R: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004, 110:214-219.
40. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003, 290:480-494.
41. Hanefeld M, Chiasson JL, Koehler C, et al.: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004, 35:1073-1078.
42. Monnier L, Colette C, Lapinski H, Boniface H: Self-monitoring of blood glucose in diabetic patients: From the least common denominator to the greatest common multiple. Diabetes Metab 2004, 20:113-119.
43. Wolever TM: The glycemic index. In: Aspects of Some Vitamins, Minerals and Enzymes in Health and Disease. Edited by Bourne GH. Basel, Switzerland: Karger; 1990:120-185.
44. Nathan DM: Finding new treatments for diabetes - how many, how fast... how good? N Engl J Med 2007, 356:437-440.
45. Breuer HW: Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 2003, 41:421-440.
46. Culy CRA Jarvis B: Repaglinide: a review of its therapeutic use in type 2 diabetes. Drugs 2001, 61:1625-1660.
47. Sinclair EM, Drucker DJ: Glucagon-like peptide 1 agonists and dipeptidyl peptidase IV inhibitors: New therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabetes 2005, 12:146-151.
48. Hirsch IB: Insulin analogs. N Engl J Med 2005, 352:174-183.
49. Monnier L, Aolette C, Owens DR: Type 2 diabetes: a well characterized but suboptimally controlled disease. Can we bridge the divide? Diabetes Metab 2008, 34:207-216.
50. Nathan DM, Buse JB, Davidson MB, et al.: Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2006, 29:1963-1972.
51. Lebovitz HE: InsuOin secretagogues: old and new. Diabetes Rev 1999, 7:139-153.